National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Childhood Ependymoma Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 11/26/2008



Purpose of This PDQ Summary






General Information






Histopathologic Classification of Childhood Ependymoma






Stage Information






Treatment Option Overview






Treatment of Newly Diagnosed Childhood Ependymoma






Treatment of Recurrent Childhood Ependymoma






Get More Information From NCI






Changes to This Summary (11/26/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Histopathologic Classification of Childhood Ependymoma

The classification of brain tumors is based on both histopathological characteristics and location in the brain. Ependymomas are divided into the following categories:

  • Subependymoma (World Health Organization [WHO] Grade I).


  • Myxopapillary ependymoma (WHO Grade I).


  • Ependymoma (WHO Grade II). Variants include cellular, papillary, tanycytic, clear cell, and mixed.


  • Anaplastic (also known as malignant) ependymoma (WHO Grade III).


The most recent WHO classification of brain tumors maintains the term “ependymoma” for tumors that are histologically benign and malignant ependymoma for those that have malignant characteristics.[1] These categories are based on the nuclear/cytoplasmic ratio, number of nuclei and mitotic figures, and the degree of nuclear atypia. Contemporary studies have failed to show significant differences in how these tumors behave on the basis of histologic classification alone,[2-5] although a small experience from a single-institution study suggested that patients with clear cell ependymoma may be at higher risk for treatment failure,[6] confirmation is required in a larger group of unselected patients. Myxopapillary ependymomas, which typically present in the filum terminale and cauda equina, are also considered a separate entity. Ependymoblastomas (for more information, refer to the PDQ summary Childhood Central Nervous System Embryonal Tumors), which generally behave more like medulloblastomas or cortical neuroectodermal tumors, are considered separate entities from ependymomas and are now classified with the embryonal tumors.[1]

The pathologic classification of pediatric brain tumors is a specialized area that is undergoing evolution; review of the diagnostic tissue by a neuropathologist who has particular expertise in this area is strongly recommended.

References

  1. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3 (3): 255-68, 1993.  [PUBMED Abstract]

  2. Goldwein JW, Leahy JM, Packer RJ, et al.: Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 19 (6): 1497-502, 1990.  [PUBMED Abstract]

  3. Rousseau P, Habrand JL, Sarrazin D, et al.: Treatment of intracranial ependymomas of children: review of a 15-year experience. Int J Radiat Oncol Biol Phys 28 (2): 381-6, 1994.  [PUBMED Abstract]

  4. Chiu JK, Woo SY, Ater J, et al.: Intracranial ependymoma in children: analysis of prognostic factors. J Neurooncol 13 (3): 283-90, 1992.  [PUBMED Abstract]

  5. Pollack IF, Gerszten PC, Martinez AJ, et al.: Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37 (4): 655-66; discussion 666-7, 1995.  [PUBMED Abstract]

  6. Fouladi M, Helton K, Dalton J, et al.: Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer 98 (10): 2232-44, 2003.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov